NCT06507917 Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV
| NCT ID | NCT06507917 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de la Réunion |
| Condition | HPV Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 398 participants |
| Start Date | 2025-11-28 |
| Primary Completion | 2026-12-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 398 participants in total. It began in 2025-11-28 with a primary completion date of 2026-12-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Anal canal cancers are on the increase in France, with around 2,000 new cases per year. These lesions can be detected by directed biopsies or smear tests. The incidence rate of anal cancer is 30 times higher in people living with HIV than in the general population. According to a recent study, the risk of anal cancer is highest in this population, but is also high in heterosexual men over 30 and women over 30. However, the proposal of a proctological examination in this population is not systematic. In France, there is no HPV screening for people living with HIV, but there is a recommendation for proctology consultation in certain cases, notably for men who have sex with men (MSM) or for women with vaginal cervical lesions. Several oncogenic HPV serotypes have been identified in the genesis of anal cancer. The serotype identified as the most carcinogenic is HPV-16 (89%). This study will look at anal HPV screening in people over 30 living with HIV, thus including a population for which no screening is currently offered (heterosexual men living with HIV and women living with HIV without vaginal cervical lesions), and will assess the concordance and acceptability of self-screening versus screening by a healthcare professional as part of a comprehensive anal cancer screening strategy in this population.
Eligibility Criteria
Inclusion Criteria: Patient : * living with HIV * aged 30 or over * resident on Reunion island and followed at the University Hospital of Reunion Island (the only follow-up center on the island) * Able to perform anal self-sampling * Able to answer a questionnaire * Affiliated with or benefiting from a social security scheme * Have given free, informed and signed consent Exclusion Criteria: * People with a previous anal swab less than 7 days old * Persons with a known current diagnosis of anal cancer * Persons deprived of liberty by judicial or administrative decision, minors, and persons under legal protection: guardianship or curators
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06507917 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, studying HPV Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06507917 currently recruiting?
Yes, NCT06507917 is actively recruiting participants. Contact the research team at lucie.auzanneau@chu-reunion.fr for enrollment information.
Where is the NCT06507917 trial being conducted?
This trial is being conducted at Saint-Denis, Reunion, Saint-Pierre, Reunion.
Who is sponsoring the NCT06507917 clinical trial?
NCT06507917 is sponsored by Centre Hospitalier Universitaire de la Réunion. The trial plans to enroll 398 participants.